StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
Huagongshe Open Project:[email protected]KI-Anbindung: llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.7.8
  1. Startseite
  2. /Verbindung

Kynurenic Acid

HCID 3845
NotizenReaktionen
GrundinformationenNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
13593-94-7
Standard-SMILES
O=C(O)c1cc(=O)c2ccccc2[nH]1
InChIKey
HCZHHEIFKROPDY-UHFFFAOYSA-N
Summenformel
C10H7NO3
Durchschnittliche Molmasse
189,17 g/mol
Monoisotopische Masse
189,04259309

Namen und Bezeichner

Bevorzugter Name
Kynurenic Acid
IUPAC
4-oxo-1H-quinoline-2-carboxylic acid
Englischer Name
1,4-DIHYDRO-4-OXOQUINOLINE-2-CARBOXYLIC ACID
Summenformel
C10H7NO3
Molmasse
189.17

Namen und Synonyme

kynurenic acid492-27-34-Hydroxyquinoline-2-carboxylic acidKinurenic acidKynuronic acidQuinurenic acid4-Hydroxyquinaldic acid2-Quinolinecarboxylic acid, 4-hydroxy-4-Hydroxy-2-quinolinecarboxylic acid4-Hydroxyquinaldinic acid4-oxo-1H-quinoline-2-carboxylic acidNSC-58973
Weitere Namen anzeigen
4-OXO-1,4-DIHYDROQUINOLINE-2-CARBOXYLIC ACIDKynurenateCCRIS 4428TranstorineQuinaldic acid, 4-hydroxy-Transtorine, 10 mM in DMSOQuinaldic acid, 4-hydroxy- (8CI)quinoline-4-one-2-carboxylic acid
CHEBI:18344H030S2S85JDTXSID8075417Acid, KynurenicRefChem:794384DTXCID5040675207-751-513593-94-7

Datenbank-Bezeichner

CAS
13593-94-7、492-27-3
PubChem CID
3845
DTXSID
DTXSID8075417
ChEMBL
CHEMBL299155
ChEBI
CHEBI:18344
UNII
H030S2S85J
EC Number
207-751-5、816-062-4
Nikkaji
J377.339F、J6.059C

Eigenschaften

Berechnete Struktureigenschaften

XLogP
1,3
Polarare Oberfläche (TPSA)
66,4 Ų
H-Brücken-Donoren
2
H-Brücken-Akzeptoren
4
Frei drehbare Bindungen
1
Schwere Atome
14
Formalladung
0
Komplexität
308

Experimentelle und physikochemische Eigenschaften

Solubility>28.4 [ug/mL] (The mean of the results at pH 7.4)
Melting Point280 °C
Physical Description · 2 Einträge

Yellow solid; [Merck Index] Yellow needles; [Alfa Aesar MSDS]

Solid

Collision Cross Section · 4 Einträge

151.1 Ų [M+Na]+ [CCS Type: DT; Method: single field calibrated with ESI Low Concentration Tuning Mix (Agilent)];136.7 Ų [M+H]+ [CCS Type: DT; Method: single field calibrated with ESI Low Concentration Tuning Mix (Agilent)];133.9 Ų [M-H]- [CCS Type: DT; Method: single field calibrated with ESI Low Concentration Tuning Mix (Agilent)]

137 Ų [M+H]+ [CCS Type: DT; Method: single field calibrated with Agilent tune mix (Agilent)];149.51 Ų [M+Na-2H]- [CCS Type: DT; Method: single field calibrated with Agilent tune mix (Agilent)]

140.99 Ų [M+H]+ [CCS Type: DT; Method: stepped-field];137.3 Ų [M-H]- [CCS Type: DT; Method: stepped-field];154.12 Ų [M+Na]+ [CCS Type: DT; Method: stepped-field]

135.3 Ų [M-H]-;151.2 Ų [M+Na]+;136.6 Ų [M+H]+

Physikochemische Eigenschaften

Schmelzpunkt
123 °C · 123 °C

Sicherheit und Regulatorisches

GHS-Klassifizierung

GHS Classification · 6 Einträge

Warning

H315 (100%): Causes skin irritation [Warning Skin corrosion/irritation];H319 (100%): Causes serious eye irritation [Warning Serious eye damage/eye irritation];H335 (97.4%): May cause respiratory irritation [Warning Specific target organ toxicity, single exposure; Respiratory tract irritation]

P261, P264, P264+P265, P271, P280, P302+P352, P304+P340, P305+P351+P338, P319, P321, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 39 reports by companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.;Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website.

Gefahrenhinweise

Regulatory Information2-Quinolinecarboxylic acid, 4-hydroxy-: Does not have an individual approval but may be used under an appropriate group standard
Hazards Summary · 1 Eintrag

Causes anticonvulsant behavior in acute intracerebral and intraperitoneal studies of mice; Causes other degenerative changes of brain and coverings in acute intracerebral studies of rats; Causes analgesia in acute intraspinal studies of rats; [RTECS] A skin and strong eye irritant; [Alfa Aesar MSDS] See Quinoline.

Hazard Classes and Categories · 2 Einträge

Skin Irrit. 2 (100%);Eye Irrit. 2 (100%);STOT SE 3 (97.4%)

Skin Irrit. 2 (100%);Eye Irrit. 2A (100%);STOT SE 3 (100%)

Toxikologische Informationen

Chemie und Industrie

Pharmakologische Informationen

Metabolism/MetabolitesUremic toxins tend to accumulate in the blood either through dietary excess or through poor filtration by the kidneys. Most uremic toxins are metabolic waste products and are normally excreted in the urine or feces.
MeSH Pharmacological ClassificationDrugs that bind to but do not activate excitatory amino acid receptors, thereby blocking the actions of agonists.
Tissue LocationsBrain;Epidermis;Fibroblasts;Placenta;Prostate
Cellular LocationsCytoplasm
Metabolite PathwaysTryptophan metabolism

Verwendung und Herstellung

Uses · 2 Einträge

A metabolite of tryptophan found in the urine of some animals; Used in nutritional studies of vitamin B deficiency; [Merck Index] A broad-spectrum excitatory amino acid antagonist used as a research tool. [ChemIDplus]

Naturally produced by the body (endogenous).

Anbieter64 Anbieter

上海康恩博医药科技有限公司17510465506 · [email protected]
上海阿拉丁生化科技股份有限公司400-6206333 13167063860 · [email protected]
湖南韵邦生物科技股份有限公司85561037 15386497078 · [email protected]
艾吉析科技(上海)有限公司17717235263 · [email protected]

Zugehörige Reaktionen

1
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 1386447
HRID 1386447als Eduktuspto-grants-2001_07

Notizen zur Verbindung

Wird geladen…

Auf dieser SeiteGrundinformationenNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
Siedepunkt
358.4 · 358.4±42.0 °C(Predicted)
Dichte
1.429 · 1.429±0.06 g/cm3(Predicted)
storage temp.
Sealed in dry,Room Temperature
Aggregatzustand
Solid
pka
3.49 · 3.49±0.20(Predicted)
Farbe
White to off-white
Treatment
Kidney dialysis is usually needed to relieve the symptoms of uremic syndrome until normal kidney function can be restored.
Health EffectsChronic exposure to uremic toxins can lead to a number of conditions including renal damage, chronic kidney disease and cardiovascular disease.
Exposure RoutesEndogenous, Ingestion, Dermal (contact)
Toxicity Summary · 1 Eintrag

Uremic toxins such as kynurenic acid are actively transported into the kidneys via organic ion transporters (especially OAT3). Increased levels of uremic toxins can stimulate the production of reactive oxygen species. This seems to be mediated by the direct binding or inhibition by uremic toxins of the enzyme NADPH oxidase (especially NOX4 which is abundant in the kidneys and heart) (A7868). Reactive oxygen species can induce several different DNA methyltransferases (DNMTs) which are involved in the silencing of a protein known as KLOTHO. KLOTHO has been identified as having important roles in anti-aging, mineral metabolism, and vitamin D metabolism. A number of studies have indicated that KLOTHO mRNA and protein levels are reduced during acute or chronic kidney diseases in response to high local levels of reactive oxygen species (A7869).

Signs and Symptoms · 1 Eintrag

As a uremic toxin, this compound can cause uremic syndrome. Uremic syndrome may affect any part of the body and can cause nausea, vomiting, loss of appetite, and weight loss. It can also cause changes in mental status, such as confusion, reduced awareness, agitation, psychosis, seizures, and coma. Abnormal bleeding, such as bleeding spontaneously or profusely from a very minor injury can also occur. Heart problems, such as an irregular heartbeat, inflammation in the sac that surrounds the heart (pericarditis), and increased pressure on the heart can be seen in patients with uremic syndrome. Shortness of breath from fluid buildup in the space between the lungs and the chest wall (pleural effusion) can also be present.

Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).

Regulatorische Informationen

Regulatory Information2-Quinolinecarboxylic acid, 4-hydroxy-: Does not have an individual approval but may be used under an appropriate group standard

Sicherheitsdaten

hazard_class
IRRITANT
杭州品高化工有限公司
0571-87658025 · [email protected]
上海毕得医药科技股份有限公司400-1647117 13681763483 · [email protected]
安徽勇晟医药科技有限公司181-3307-5798 18017383231 · [email protected]
江苏艾康生物医药研发有限公司025-66061636 19370895928 · [email protected]
武汉众志诚生物技术有限公司13628624121 13628604890 · [email protected]
上海赛可锐生物科技有限公司021-58000709 13120558703 · [email protected]
Sinco Pharmachem (ShenZhen) R&D Co., Ltd.+86-18603013401 · [email protected]
大连美仑生物技术有限公司0411-62910999 13889544652 · [email protected]
成都添福瑞生物科技有限公司18030648795 18030648795 · [email protected]
成都梓永智研生物科技有限公司17780686372 · [email protected]
苏州施亚生物科技有限公司17715136450 · [email protected]
上海诗丹德标准技术服务有限公司021-021-57127007-6622-6622 17621252073 · [email protected]
成都普思生物科技股份有限公司028-85370565-229 18080489829 · [email protected]
怀化市冰峰化工有限公司0745-2866851 17711757908 · [email protected]
上海相辉医药科技有限公司13761987713; 13761987713 · [email protected]
銳迪國際科技有限公司18024082417 · [email protected]
上海维亦特生物科技有限公司15317051735 · [email protected]
BOC Sciences1-631-485-4226; 16314854226 · [email protected]
宝鸡缔都医药化工有限公司029-81145305 17791533577 · [email protected]
杭州云易国科生物科技有限公司18457506494 · [email protected]
上海旭晗化学科技有限公司15921303235 · [email protected]
郑州安步防护用具有限公司+86-0371-88006763; +86-15988602810 · [email protected]
上海毕得医药科技股份有限公司400-164-7117 18317119277 · [email protected]
天津普西唐生物医药科技有限公司010-60605840 · [email protected]
武汉天植生物技术有限公司18607101326 15172504745 · [email protected]
四川精萃天成药物科技有限公司028-87865381 18108190480 · [email protected]
上海任跃化学科技有限公司021-62219190; 18321139117 · [email protected]
上海谱振生物科技有限公司4001650900 13817534909 · [email protected]
上海超岚化工科技中心(原宁波市超明生物科技有限公司)13301662590 · [email protected]
上海阿拉丁生化科技股份有限公司6206333 13167063860 · [email protected]
武汉福鑫化工有限公司+86-2759207851; +86-18007136271 · [email protected]
风咏生物(AbMole)021-10000000 13000000000 · [email protected]
上海源叶生物科技有限公司13636370518 · [email protected]
浙江麦格生物医药有限公司4000-156-528 13355733872 · [email protected]
Shanghai Acmec Biochemical Technology Co., Ltd.+86-18621343501 · [email protected]
上海泰坦科技股份有限公司18616708014 · [email protected]
上海康恩博医药科技有限公司400-1388-521 17510465506 · [email protected]
上海吉至生化科技有限公司021-4009004166/18616739031 18616739031 · [email protected]
北京沃凯生物科技有限公司010-62971590 18548936886 · [email protected]
北京迈瑞达科技有限公司010-82387566 · [email protected]
南京狄尔格医药科技有限公司025-025-51191215 18013836722 · [email protected]
深圳利斯康医药科技有限公司+86-755-89396905 +86-15013857715 · [email protected]
湖北摩科化学有限公司18627753421; 18627756402 · [email protected]
Aladdin Scientific[email protected]
上海皓鸿生物医药科技有限公司400-8210725 4008210725 · [email protected]
SHANGHAI KEAN TECHNOLOGY CO., LTD.+8613817748580 · [email protected]